Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) represent major global health burdens, collectively affecting hundreds of millions worldwide.1 COPD is projected to become the third leading cause of death globally by 2030, while CVD remains the primary cause of mortality worldwide.2 Historically viewed as distinct entities, a paradigm shift is underway as mounting evidence reveals a complex, bi-directional relationship between these conditions.3,4 This growing recognition extends beyond shared risk factors like smoking, encompassing common pathophysiological mechanisms, such as systemic inflammation and oxidative stress.5 The interplay between COPD and CVD presents unique challenges and opportunities, necessitating a re-evaluation of traditional management approaches and calling for more integrated, multi-disciplinary care strategies.
Mechanisms linking COPD and CVD
The interrelationship between COPD and CVD is underpinned by several interconnected pathophysiological mechanisms.3,5 Chronic systemic inflammation, a hallmark of COPD, extends beyond the lungs, contributing to atherosclerosis and cardiovascular dysfunction.5 Elevated levels of inflammatory markers such as C-reactive protein and interleukin-6 are observed in both conditions, suggesting a shared inflammatory pathway.6
Oxidative stress, another key feature of COPD, leads to endothelial dysfunction and vascular damage, accelerating the progression of CVD.7 This is exacerbated by shared risk factors, particularly smoking, which not only initiates and perpetuates both conditions but also amplifies their detrimental effects on the cardiopulmonary system.7
Chronic hypoxia in COPD patients triggers compensatory mechanisms that strain the cardiovascular system.8 It induces pulmonary vasoconstriction, leading to pulmonary hypertension and subsequent right ventricular dysfunction.8 This right-sided heart stress can eventually impact left ventricular function, contributing to overall cardiac impairment.8
Moreover, repeated episodes of hypoxia and hypercapnia in COPD, especially during exacerbations, can increase sympathetic nervous system activity and arterial stiffness, further elevating cardiovascular risk.9,10 Understanding these intricate connections is crucial for developing comprehensive management strategies that address both the pulmonary and cardiovascular aspects of patient care.
Clinical implications
The intertwined nature of COPD and CVD presents significant clinical challenges. COPD patients face a markedly increased risk of cardiovascular events, with studies showing a two- to five-fold higher incidence of coronary artery disease and heart failure compared with the general population.11,12 This elevated risk necessitates a paradigm shift in disease management, calling for integrated treatment strategies that address both respiratory and cardiovascular health simultaneously.
The overlap in symptoms between COPD and CVD, such as dyspnoea and fatigue, can complicate diagnosis and delay appropriate treatment.13 Clinicians must maintain a high index of suspicion for concurrent CVD in COPD patients, employing careful clinical assessment and appropriate diagnostic tools to differentiate between exacerbations of COPD and acute cardiovascular events.
Furthermore, treatment decisions become more complex, requiring a delicate balance between managing COPD symptoms and mitigating cardiovascular risk. For instance, the use of beta blockers, crucial in many cardiovascular conditions, must be carefully considered in COPD patients due to potential bronchoconstriction.14 This underscores the need for a multi-disciplinary approach to patient care, involving both pulmonologists and cardiologists in treatment planning and long-term management.
Current research and evidence
Recent epidemiological studies have solidified the COPD–CVD link, with large-scale analyses like the SUMMIT trial demonstrating significantly increased cardiovascular risk in COPD patients.15 The TONADO and DYNAGITO studies have explored combined management approaches, investigating the cardiovascular safety and efficacy of dual bronchodilator therapies in COPD patients with comorbid CVD.16,17
Emerging research focuses on identifying novel biomarkers for early detection and risk stratification. Promising candidates include serum fibrinogen and high-sensitivity C-reactive protein, which may predict both COPD exacerbations and cardiovascular events.15-17 The ongoing CAPTURE study aims to validate a simple, five-step approach to identify COPD patients at high risk for exacerbations or serious cardiac events, potentially revolutionising risk assessment in clinical practice.18
These advancements underscore the growing emphasis on integrated approaches to COPD and CVD management, paving the way for more personalised and effective treatment strategies.
Therapeutic considerations
Managing patients with co-existing COPD and CVD requires a nuanced approach to pharmacological interventions. While bronchodilators remain the cornerstone of COPD treatment, their cardiovascular safety profile must be considered. Conversely, statins have shown potential benefits in COPD beyond their cardioprotective effects, possibly due to their anti-inflammatory properties.19
Non-pharmacological interventions play a crucial role. Pulmonary rehabilitation programmes can improve exercise capacity and quality of life while potentially reducing cardiovascular risk. Lifestyle modifications, including smoking cessation and physical activity, are paramount in managing both conditions.4,5
Clinicians must be vigilant about the potential cardiovascular effects of COPD medications. For instance, while long-acting beta-agonists are generally safe, they may increase heart rate and the risk of arrhythmias in susceptible individuals.14 This underscores the importance of personalised treatment plans that balance respiratory benefits with cardiovascular safety.
Challenges in COPD–CVD management
The co-management of COPD and CVD presents significant challenges. Underdiagnosis and undertreatment of both conditions are common, often due to overlapping symptoms and the focus on managing the perceived ‘primary’ disease.13 This can lead to missed opportunities for early intervention and comprehensive care.
Polypharmacy is a major concern, with patients often requiring multiple medications for both conditions. This increases the risk of drug interactions and adverse effects, necessitating careful medication reconciliation and monitoring.4
Balancing respiratory and cardiovascular treatment goals can be complex. For instance, beta blockers, crucial for many cardiovascular conditions, may worsen bronchospasm in COPD.14 Conversely, some COPD medications can have adverse cardiovascular effects.4 This delicate balance requires individualised treatment approaches, and often necessitates collaboration between pulmonologists and cardiologists to optimise patient outcomes.
Future directions
Ongoing trials, like ETHOS and KRONOS, explore novel therapies targeting both COPD and CVD pathways, with promising potential for dual-action drugs.20,21 Emerging precision medicine approaches targeting individual inflammatory profiles and genetic markers may revolutionise treatment for overlapping pathologies. A growing emphasis on integrated care models aims to provide comprehensive care, potentially improving outcomes for those with co-existing COPD and CVD.
Key messages
- Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) share pathophysiological mechanisms, mutually impacting disease progression
- Co-existing COPD and CVD increase morbidity and mortality, necessitating early detection and comprehensive care
- Managing COPD–CVD comorbidity requires balancing treatments and considering drug interactions
- Stakeholders must prioritise integrated care, enhanced screening, and targeted research to improve COPD–CVD outcomes
Conflicts of interest
None declared.
Funding
None.
References
1. Viegi G, Maio S, Fasola S, Baldacci S. Global burden of chronic respiratory diseases. J Aerosol Med Pulm Drug Deliv 2020;33:171–7. https://doi.org/10.1089/jamp.2019.1576
2. López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology 2016;21:14–23. https://doi.org/10.1111/resp.12660
3. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 2018;12:1753465817750524. https://doi.org/10.1177/1753465817750524
4. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018;27:180057. https://doi.org/10.1183/16000617.5057-2018
5. Rogliani P, Ritondo BL, Laitano R, Chetta A, Calzetta L. Advances in understanding of mechanisms related to increased cardiovascular risk in COPD. Expert Rev Respir Med 2021;15:59–70. https://doi.org/10.1080/17476348.2021.1840982
6. Ghoorah K, De Soyza A, Kunadian V. Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review. Cardiol Rev 2013;21:196–202. https://doi.org/10.1097/CRD.0b013e318279e907
7. Shaito A, Aramouni K, Assaf R et al. Oxidative stress-induced endothelial dysfunction in cardiovascular diseases. Front Biosci (Landmark Ed) 2022;27:105. https://doi.org/10.31083/j.fbl2703105
8. Lucero García Rojas EY, Villanueva C, Bond RA. Hypoxia inducible factors as central players in the pathogenesis and pathophysiology of cardiovascular diseases. Front Cardiovasc Med 2021;8:709509. https://doi.org/10.3389/fcvm.2021.709509
9. Simons SO, Heptinstall AB, Marjenberg Z et al. Temporal dynamics of cardiovascular risk in patients with chronic obstructive pulmonary disease during stable disease and exacerbations: review of the mechanisms and implications. Int J Chron Obstruct Pulmon Dis 2024;19:2259–71. https://doi.org/10.2147/COPD.S466280
10. Sarkar M, Madabhavi I, Kadakol N. Oxygen-induced hypercapnia: physiological mechanisms and clinical implications. Monaldi Arch Chest Dis 2022;93:2399. https://doi.org/10.4081/monaldi.2022.2399
11. Cavaillès A, Brinchault-Rabin G, Dixmier A et al. Comorbidities of COPD. Eur Respir Rev 2013;22:454–75. https://doi.org/10.1183/09059180.00008612
12. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165–85. https://doi.org/10.1183/09031936.00128008
13. Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agustí A. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am J Respir Crit Care Med 2016;194:1319–36. https://doi.org/10.1164/rccm.201604-0690SO
14. Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. Eur Respir J 2016;48:880–8. https://doi.org/10.1183/13993003.01847-2015
15. Kunisaki KM, Dransfield MT, Anderson JA et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med 2018;198:51–7. https://doi.org/10.1164/rccm.201711-2239OC
16. Ferguson GT, Maltais F, Karpel J et al. Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies. NPJ Prim Care Respir Med 2020;30:53. https://doi.org/10.1038/s41533-020-00212-w
17. Ferguson GT, Buhl R, Bothner U et al. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respir Med 2018;143:67–73. https://doi.org/10.1016/j.rmed.2018.08.012
18. Yawn BP, Han M, Make BM et al. Protocol summary of the COPD assessment in primary care to identify undiagnosed respiratory disease and exacerbation risk (CAPTURE) validation in primary care study. Chronic Obstr Pulm Dis 2021;8:60–75. https://doi.org/10.15326/jcopdf.2020.0155
19. Young RP, Hopkins RJ. Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. Expert Rev Respir Med 2013;7:533–44. https://doi.org/10.1586/17476348.2013.838018
20. Singh D, Martinez FJ, Hurst JR et al. Effect of triple therapy on cardiovascular and severe cardiopulmonary events in COPD: a post-hoc analysis of a randomized, double-blind, phase 3 clinical trial (ETHOS). Am J Respir Crit Care Med 2025;211:205–14. https://doi.org/10.1164/rccm.202312-2311OC
21. Ferguson GT, Rabe KF, Martinez FJ et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018;6:747–58. https://doi.org/10.1016/S2213-2600(19)30006-2
